Traws Pharma, Inc. is a biopharmaceutical company developing innovative therapies in virology, oncology, and rare diseases, engaging in research, licensing, and potential commercialization activities.

# Company Summary - Traws Pharma, Inc.

**Overview:**  
Traws Pharma, Inc. is a biopharmaceutical company focused on the development of innovative therapies, particularly in the areas of virology, oncology, and rare diseases. The company is involved in research, development, licensing, and potential commercialization of drug candidates aimed at viral diseases and cancers.

**Key Details from the Filing:**  
- **Business Focus:** Development of drug candidates for viral diseases and oncology.  
- **Location:** 12 Penns Trail, Newtown, PA 18940, United States.  
- **Stock Information:**  
  - Shares Outstanding as of April 28, 2025: 5,334,015 shares  
  - Trading Symbol: TRAW on The Nasdaq Stock Market LLC.  
- **Market Capitalization (as of most recent reporting date):** approximately $9.6 million (based on last sale price of stock held by non-affiliates).  

**Company Size & Financials:**  
- **Employees:** The document does not specify the total number of employees.  
- **Customers:** The document does not specify the number of customers.  
- **Revenue and Income:** The filing does not provide specific financial figures such as revenue, net income, or other financial performance metrics. It primarily discusses corporate governance, executive compensation, and director details.

**Corporate Governance & Operations:**  
- **Board of Directors:** Composed of six members with experience in pharmaceutical leadership, finance, and research.  
- **Executives:** Includes roles such as Interim CEO, Chief Medical Officers, Chief Operating Officer, and others with backgrounds in biotech, medicine, and investment.  
- **Business Strategy:** Focuses on research, licensing agreements (e.g., Viriom patents and drug development licenses), and partnerships with CROs and investment entities.  
- **Recent Activity:** The company had an acquisition of Trawsfynydd, which involved the transfer of license rights and ongoing research collaborations with entities like Viriom, ChemDiv, and Expert Systems.

**Note:**  
No specific operational metrics such as revenue, net income, customer count, or employee numbers are provided in this section of the 10-K/A. The document mainly covers governance, executive details, and recent strategic activities.

Traws Pharma, Inc. is a biopharmaceutical company focused on innovative therapies for oncology and virology, backed by strategic growth initiatives and a strong research pipeline.

# Traws Pharma, Inc. Overview

Traws Pharma, Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of innovative therapies for various medical conditions, particularly in the fields of oncology and virology. The company focuses on developing novel compounds and therapies through rigorous scientific and clinical methodologies.

## Key Details

- **Founded**: Traws Pharma, Inc. was incorporated in the state of Delaware and has grown significantly through strategic hires and research initiatives.
  
- **Headquarters**: 12 Penns Trail, Newtown, PA, 18940, United States.

### Business Focus

Traws Pharma specializes in:
- **Oncology**: Developing treatments for various cancers, with a focus on targeted therapies that aim to improve patient outcomes with minimum side effects.
- **Virology**: Focusing on the development of treatments for viral diseases, specifically through innovative research collaborations.

## Financial Performance

- **Revenue**: For the fiscal year ended December 31, 2023, Traws Pharma reported revenues, although the specific revenue figure is not disclosed in the provided information.
- **Income**: The company is in the developmental phase; thus, it may be operating at a loss as it invests heavily in research and development (R&D).
  
### Customer Base

- **Customers**: The company primarily engages with healthcare professionals, institutions, and potential licensing partners for its products. Specific customer numbers are not disclosed.
- **Collaborations**: Traws Pharma has entered into agreements with companies like Viriom, which enhance its research capabilities and market reach.

### Workforce

- **Employees**: Traws Pharma employs a team of highly qualified professionals, including scientists, biopharmaceutical executives, and support staff. The exact number of employees is not specified, but the leadership team and board of directors are composed of experienced individuals from the pharmaceutical industry.

### Research and Development

- **Pipeline Products**: The company has a robust pipeline of drug candidates aimed at addressing unmet medical needs in oncology and virology.
- **Clinical Trials**: Traws Pharma is actively involved in clinical trials to evaluate the safety and efficacy of its products, which is a critical component of the biopharmaceutical development process.

## Conclusion

Traws Pharma, Inc. is positioned as a significant player in the biopharmaceutical sector, focusing on innovative therapies for oncology and viral diseases. While specific financial metrics like revenue and income are not detailed, the company is structured for growth, backed by an experienced leadership team and strategic collaborations that aim to enhance its product development initiatives.

Traws Pharma, Inc.

10-K / April 30, 2025

10-K / April 29, 2024

10-K / April 30, 2025

Company Summary - Traws Pharma, Inc.